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Nogo has been proposed to be amajor
myelin-derived inhibitor of axon re-
generation in the mammalian central
nervous system (CNS). Three studies
tested this hypothesis by assessing
regeneration in various Nogo-deficient
mice following spinal cord injury (Kim
et al., 2003; Simonen et al., 2003;
Zheng et al., 2003), yet different regen-
erative responses were reported. In
studies of a Nogo gene trap mutant,
Kim et al. (2003) reported dramatically
enhanced sprouting above the lesion,
reflected by the presence of CST
axons in ectopic locations (the lateral
funiculus ipsilateral to the injection) in
all (12/12) Nogo knockout mice. Evi-
dence of striking long-distance regen-
eration was the presence of ectopic
BDA-labeled axons more than 5 mm
caudal to the injury in 7/11 Nogo
knockout mice that received spinal
cord injuries at 7.5–9 weeks of age.
Three mice that underwent surgery at
11–14 weeks of age did not exhibit ev-
idence of long-distance regeneration.
The labeled axons in caudal segments
seemed to be especially compelling
evidence of robust but disorderly re-
generation of the CST because labeled
axons were present bilaterally in the
lateral funiculus (an ectopic location).
In contrast, Simonen et al. (2003)
reported increased sprouting near
the lesion site in a Nogo-A-targeted
knockout (in which Nogo-B expression
was upregulated) and evidence for en-
hanced regeneration below the lesion
in a subset (4/16) of mutants, although
there was no statistically significant
difference between knockout and con-
trols. Our group found no statisticallysignificant difference between Nogo-
A,B (or Nogo-A,B,C) mutants andwild-
type controls in the extent of CST
sprouting above the lesion or regener-
ation past the lesion (Zheng et al.,
2003). One enigmatic finding was that
ectopic axons similar to those re-
ported by Kim et al. were observed in
one control mouse (see Figure S2 in
the Supplemental Data of Zheng
et al., 2003).
Possible reasons for the discrepant
results have been discussed (Woolf,
2003), but there has been no satisfac-
tory explanation of the apparently ro-
bust regeneration in one study and
modest or no enhanced regeneration
in the others. Accordingly, we set out
to perform a full replication of the ex-
periments in the knockout line used
in our study (Zheng et al., 2003) and
the gene trap line used by Kim et al.
(2003), which were reported to exhibit
striking regeneration. In the course of
our studies, we discovered that axons
in the white matter stain artifactually
when BDA leaks into the cerebrospinal
fluid (CSF) in the cerebral ventricle,
producing a pattern of ectopic labeled
axons that is remarkably similar to
what was interpreted as massive
sprouting/regeneration by Kim et al.
In this report, we document the artifac-
tual labeling, show that it occurs as
a result of BDA entering the CSF, and
demonstrate that the artifact may be
avoided by delaying the tract tracing
injections for 4 weeks after spinal
cord lesions.
Results
In all three studies of Nogo knockout
mice, regeneration was assessed fol-lowing transection of the dorsal half
of the spinal cord (a dorsal hemi-
section) at T8, which in mice interrupts
descending CST axons while sparing
white matter and gray matter in ventral
portions of the spinal cord. Possible
regeneration of cortico-spinal tract
(CST) axons was then assessed by
injecting biotinylated dextran amine
(BDA) into the sensorimotor cortex.
Importantly, all three studies used a
similar, short-term protocol: the corti-
cal BDA injection was made in the
same operative procedure as the spi-
nal cord lesion, and regeneration was
assessed 2–3 weeks later.
In our replication experiment, we
used the same protocol to assess pos-
sible CST regeneration in homozygous
mutant and control (wild-type and het-
erozygotes). BDA was injected using
the coordinates described in Zheng
et al. (2003) (Kim et al. [2003] did not
report their coordinates). One small
procedural difference that turned out
to be important was that, in our previ-
ous study (Zheng et al., 2003), BDA
was injected at a depth of 0.5 mm in
the cortex, whereas in the repeat
experiment we lowered the syringe
below 0.5 mm and then withdrew to
the final location. This was done to
achieve greater accuracy because
the cortex is frequently displaced
slightly as the microsyringe is lowered.
As discussed below, this had the unin-
tended consequence that the syringe
sometimes penetrated the ventricle.
In intact mice (that is, without spinal
cord injuries), injections of BDA into
the sensorimotor cortex produce
robust labeling of dorsal main CST in
the ventral part of the dorsal column
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CorrespondenceFigure 1. Ectopic BDA-Labeled Axons in Control Mice that Receive Dorsal
Hemisection Injuries and BDA Injections into the Sensorimotor Cortex
(A) Distribution of CST axons in normal C57BL/6 mice. The main component of CST axons (called
the dorsal CST) descends in the ventral part of the dorsal column (DCST). A smaller component of
CST axons travels in the dorsal part of the lateral funiculus (the dorsolateral CST, abbreviated
DLCST). CST axons arborize extensively in the gray matter.
(B and C) Ectopic axonal labeling was discovered in experiments in which mice received BDA in-
jections at the time of a spinal cord injury, where large numbers of ectopic axons are evident on
both sides in sections taken rostral (B) and caudal (C) to the injury. (B) and (C) illustrate sections
froma heterozygous control taken rostral (B) and caudal (C) to a dorsal hemisection lesion. The ver-
tical line in (B) indicates the approximate mediolateral location of the sagittal section shown in (D).
(D) Sagittal section at the injury site (from the animal illustrated in panels [B] and [C]) reveals BDA-
labeled axons on both sides of the lesion, especially in the lateral funiculus rostral to the injury.
(E) Injection site in the cerebral cortex for the mouse illustrated in (A)–(D). Arrows indicate BDA
labeling in ependymal cells lining the ventricle.and the dorsolateral CST in the dorsal
part of the lateral column (Figure 1A
and Steward et al., 2004). A few BDA-
labeled axons are sometimes seen in
the dorsal column and dorsal lateral fu-
niculus ipsilateral to the injection rep-
resenting an uncrossed component
of CST axons that travel in the location
of the main tracts. We have not seen
evidence of a ventral CST in mice
(that is, BDA-labeled longitudinal
axons in the ventral column ipsilateral192 Neuron 54, April 19, 2007 ª2007 Elsto the injection), although BDA-labeled
collaterals can be seen extending from
the gray matter into the ventral col-
umn. In addition to the longitudinal
CST axons, BDA-labeled terminal ar-
bors are present throughout the gray
matter on the side contralateral to the
injection (ipsilateral to the main de-
scending tracts), and axon collaterals
recross the midline to form sparse
terminal arbors on the side ipsilateral
to the injection.evier Inc.In our repeat experiment, we were
surprised to find a dramatic pattern of
ectopic axonal labeling in both knock-
out and control mice comparable to
the pattern seen in Nogo knockout
mice by Kim et al. (2003). Figures 1B–
1C illustrate a heterozygous control in
which this pattern was observed. Ros-
tral to the lesion (Figure 1B), there are
abundant BDA-labeled axons in ec-
topic locations in the lateral funiculus
both ipsilateral and contralateral to
the main tract. Below the lesion (Fig-
ure 1C), ectopic axons are abundant
in the lateral funiculus on both sides,
whereas there were no BDA-labeled
axons in either the main tract (the
DCST) or the DLCST in caudal sec-
tions. This highly resembles the pat-
tern that Kim et al. interpreted as
robust sprouting/regeneration.
Above the injury, labeled axonswere
seen in ectopic locations in 4/6 wild-
type mice, 9/12 heterozygotes, and
7/15 knockout mice; below the injury,
ectopic axons were present in 3/6
wild-type mice, 5/12 heterozygotes,
and 7/15 knockouts. Assessment of
the subset of mice that did not exhibit
ectopic labeled axons (2/6 wild-types,
3/12 heterozygotes, and 5/15 homozy-
gous knockouts) revealed no other ob-
vious indication of enhanced regener-
ation in the knockout mice compared
to controls. It remains to be seen
whether a more subtle regeneration
phenotype can be detected in quanti-
tative analyses using techniques that
avoid the artifact we describe here.
BDA-labeled axons in ectopic loca-
tions had a distinctly different appear-
ance from the bona fide labeled axons
in the DCST and DLCST. First, they
were larger, which is surprising if they
actually were regenerated axons. Fig-
ure 2 illustrates this in a different case
than shown in Figures 1A–1E. Second,
ectopic axons had a ‘‘hollow’’ appear-
ance, suggesting that labeling was as-
sociated with the outside of the axon
or perhaps even the myelin sheath
rather than the core of the axon. The
hollow appearance can best be seen
by focusing up and down in the micro-
scope (see Movies S1 and S2 in the
Supplemental Data available with this
article online). Third, labeled axons in
ectopic locations are not as strongly
Neuron
CorrespondenceFigure 2. Ectopic Axons Have a Different Appearance Than Bona Fide Labeled Axons
(A) The section is taken from another animal, illustrating that ectopic axons appear larger than bona fide labeled axons in the main tracts. Note that
some of the axons on the right side are in ectopic locations (ventral to the main contingent of fibers in the DLCST), and these appear larger than the
bona fide labeled axons in the main tracts.
(B) High-magnification view of ectopic axons. Note that the axons appear hollow and in general are more lightly labeled than the bona fide labeled
axons in the main DCST.
(C) Labeled axons in the DCST.
(D) No ectopic axons are seen in mice that received BDA injections 4 weeks after a dorsal hemisection injury.reflective in dark field illumination as
the labeled axons in normal locations
(Figure S1). Nevertheless, the staining
does indicate the presence of BDA,
because when unstained sections are
assessed for the presence of fluores-
cence from the mini-ruby that is conju-
gated to the BDA, the ectopic axons
do show weak fluorescence (data not
shown).
The ectopic axons described above
were seen in experiments in which
BDA injections were made immedi-
ately following spinal cord injuries. To
explore whether the ectopic labeling
was related to this timing, we exam-
ined cases from another ongoing ex-
periment in which BDA injections
were made 28 days after identical dor-
sal hemisection injuries. We examined
11 control mice in this experiment;
none of the 11 exhibited ectopic
axons, although CST axons in the
normal tracts were heavily labeled.
An example is illustrated in Figure 2D.
The findings that a majority of mice
had the artifactual BDA labeling in the
short-term experiment, but that none
did in this longer-term experiment, de-
spite using an identical BDA-injection
protocol, implies that the artifactual
BDA labeling can be avoided by delay-ing the injection. The minimal delay
required to avoid artifactual labeling
remains to be defined, but a 4 week
delay appears adequate and would
be appropriate for documenting
regeneration.
We were puzzled by two aspects of
the results—the unusual appearance
of the ectopic axons and the fact that
the pattern of ectopic axonal labeling
was seen when injections were made
at the same time as the lesions, but
not when injections were delayed.
Accordingly, we began to suspect
that there might be some artifact that
accounted for the labeling of ectopic
axons, and so we analyzed the cases
carefully to try to identify a possible
source of artifact. Three clues sug-
gested that labeling might be artifac-
tual. First, in addition to the BDA-
labeled axonal retraction balls above
the lesion, reflecting transected axons
of the CST, some BDA-labeled axonal
retraction balls were present caudally
(Figure 1D). BDA-labeled retraction
balls on axons that approach the le-
sion from below cannot be explained
by transport along known pathways
from the cerebral cortex. Second,
BDA-labeled axons that passed the
lesion in ectopic locations (the lateralNeuronfuniculus) appeared straight and un-
branched, whereas a tortuous tra-
jectory is expected of an axon that
has regenerated. A third clue came
from inspection of the cortical injection
sites, as we noticed clear evidence of
BDA leakage into the cerebral ventricle
in several cases. Figure 1E illustrates
the injection site from the case shown
in Figures 1A–1D. Heavy BDA labeling
of cells in the ependymal layer reveals
that BDA did leak into the ventricle in
this case. These findings suggested
the hypothesis that the labeling of
axons in ectopic locations might be
due to leakage of BDA into the CSF
and uptake by damaged axons. To
test this directly, five wild-type mice
received spinal cord injuries followed
in the same operative procedure by
BDA injections directly into the cere-
bral ventricle and were allowed to sur-
vive for 17 days. Remarkably, 4/5 mice
exhibited substantial numbers of BDA-
labeled axons in ectopic locations in
segments rostral to the injury (repre-
sentative sections for all four are
shown in Figures 3A–3D). Interestingly,
ectopic axons were more numerous
on the side ipsilateral to the injection,
which was also true of the ectopic
axons described by Kim et al. Two of54, April 19, 2007 ª2007 Elsevier Inc. 193
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labeled ectopic axons cau-
dal to the injury (an example
from one of these mice is
shown in Figures 3E–3F),
despite the fact that there
were no BDA-labeled axons
in either the DCST or DLCST
in the sections caudal to the
lesions because the main
tracts had been interrupted
(data not shown). The pat-
tern of ectopic labeling
seen here was comparable
to the pattern of ectopic la-
beling attributed to robust
sprouting and regeneration
by Kim et al. (2003), who
similarly saw labeling below
the lesion, but only in ec-
topic locations, not the
DCST. To further test the
hypothesis that damaged
axons at the lesion site
take up BDA, another group
of five mice received dorsal
hemisection lesions and
intraventricular BDA injec-
tions and were killed 3
days later. Three days is far
too short a time for transport
of BDA from the cortex, but
if BDA is taken up by dam-
aged axons at the lesion
site, labeled axons should
be seen near the lesion
site. Indeed, 4/5 animals ex-
hibited clear BDA-labeled
axons and axonal retraction
balls in ectopic locations.
Moreover, labeling was
seen only in segments of
the axons within a few
hundred micrometers of the
lesion. Figures 3G and 3H




Here we show that injecting BDA at the
same time as a spinal cord injury, and
carrying out injections in such a way
that BDA leaks into the ventricles, pro-
duces remarkable artifactual labeling
of axons in the injured spinal cord
that is suggestive of robust regenera-
tive growth. The artifact that we docu-
ment here can explain the dramatic
pattern of ectopic axonal labeling that
seemed to be compelling evidence
for robust regeneration in one line of
Nogo knockout mice (Kim et al.,
2003). In our attempt to replicate their
results using their mice and their pro-
tocol, we observed a similar pattern
of dramatic labeling in a majority of an-
imals, regardless of genotype, that ap-
pears to be due to leakage
of BDA into the ventricles.
The similarities in labeling
patterns between the two
studies are compelling: ros-
tral to the lesion, massive
labeling of axons outside
the DCST and DLCST is ob-
served in similar locations in
their and our study; simi-
larly, in transverse sections
below the lesion site, mas-
sive labeling is seen in sev-
eral animals in ectopic loca-
tions, but not in the location
of the normal DCST.
The fact that this pattern
of ectopic axonal labeling
occurs in wild-type mice
when BDA is injected into
the ventricle certainly sug-
gests the need to reanalyze
CST regeneration in Nogo
knockout mice under condi-
tions where the chances of
artifact are minimized. One
can easily imagine how the
likelihood of artifactual la-
beling may differ across ge-
notypes, ages, or strains,
for example, because of dif-
ferences in maturation rate,
cortical thickness, or dif-
ferences in cell packing
density, which could alter
diffusion of BDA. Our results
also raise questions about
other studies that used the
strategy of injecting BDA at
the time of a spinal cord
injury. These include one
subset of studies involving
injections of peptide inhibi-
tors of Nogo (Li and Stritt-
matter, 2003) and a recent
study comparing regenera-
tive responses in Nogo
knockout mice on different
genetic backgrounds (Dimou et al.,
2006).
We focus here on the artifactual la-
beling of large axons in ectopic loca-
tions, but other populations of axons
may also be artifactually labeled, in-
cluding small axon arbors in the gray
matter. The absence of labeled ectopic
axons in given preparations does not
necessarily ensure the absence of
Figure 3. Ectopic Labeled Axons Are Seen Reliably in Mice
that Receive Spinal Cord Injuries and Intraventricular
Injections of BDA
(A)–(D) illustrate examples of ectopic axonal labeling in four C57BL/6
mice.
(E) and (F) illustrate ectopic labeled axons in sections caudal to the in-
jury in themouse illustrated in panel (B). There were no labeled axons in
either the DCST or DLCST in this mouse, confirming that the dorsal
hemisection destroyed the two main descending tracts.
(G) and (H) illustrate sagittal and cross-sections, respectively, showing
BDA-labeled axons in ectopic locations in cases that received intra-
ventricular BDA injections and were killed 3 days later (the dark area
in the upper part of [G] is a fold in the tissue). Although there were no
BDA-labeled axons in the dorsal or dorsolateral CST, BDA-labeled
axons and axonal retraction balls were evident in the ventral part of
the lateral column.
Arrows indicate BDA-labeled axons. Ipsi and Contra are with respect
to the BDA injection.194 Neuron 54, April 19, 2007 ª2007 Elsevier Inc.
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ulations. Thus, for future studies, the
most prudent approach will be to carry
out injections at some time after spinal
cord injury. Theminimal delay required
remains to be defined.
Experimental Procedures
Experimental Animals
Our repeat of the study by Kim et al. (2003)
used 8- to 10-week-old Nogo knockout mice
(the gene trap mutant that was generously
provided by these authors) and littermate
controls obtained by backcrossing homozy-
gous knockout mice to C57BL/6 mice. Young
adult (8- to 10-week-old) female mice of the
C57BL/6 strain were used in the experiment
that involved direct injections of BDA into the
cerebral ventricle. Histological procedures
were identical to those described in our previ-
ous study (Zheng et al., 2003), except as noted
above (for details, see the Supplemental
Experimental Procedures).
To determine the pattern of labeling that re-
sults when BDA is present in the cerebrospinal
fluid (CSF), five female C57BL/6 control mice
received dorsal hemisection injuries as above,
and then BDA was injected directly into the
cerebral ventricle underlying the sensorimotorResponse to Co
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Numerous in vivo pharmacological
studies have demonstrated the benefi-
cial effects of interfering with Nogo/
NgR function for axonal growth and
functional recovery after experimental
spinal cord injury (Bregman et al.,
1995; Brosamle et al., 2000; Fouad
et al., 2004; GrandPre et al., 2002; Ji
et al., 2005; Li et al., 2004, 2005; Li
and Strittmatter, 2003; Schnell and
Schwab, 1990; Wang et al., 2006).
Similar benefits are noted for stroke re-
covery (Lee et al., 2004; Papadopou-
los et al., 2002; Seymour et al., 2005).
However, genetic analysis of nogocortex. For this purpose, the Hamilton micro-
syringe was inserted to a depth of 2 mm at
a point 1 mm lateral to bregma, and 0.5 ml of
BDA was delivered. Mice were allowed to
survive for 17 days following the spinal cord
injuries/injections. A second group of five
mice received intraventricular BDA injections
and were allowed to survive for 3 days.
Histological methods were identical to our
previous study (Zheng et al., 2003). For
detailed procedures, see the Supplemental
Experimental Procedures.
Supplemental Data
The Supplemental Data for this article can
be found online at http://www.neuron.org/cgi/
content/full/54/2/191/DC1/.
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and ngr has proven inconclusive
(Woolf, 2003). Two mouse lines, here
termed nogo-abtrap/trap (Kim et al.,
2003) and nogo-aEIII/EIII (Dimou et al.,
2006; Simonen et al., 2003), show en-
hanced growth of corticospinal (CST)
axons after dorsal hemisection. In
contrast, another line, here termed
nogo-abatg/atg (Zheng et al., 2003), fails
to show a regenerative phenotype.
Common to each of these studies
was the observation that myelin pre-
pared from mutant mice was signifi-
cantly less inhibitory to neurite out-
growth in vitro. Among the factors
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that might explain the varied in vivo
outcomes are age at the time of lesion,
mouse strain background, surgical
techniques, axonal tracing methodol-
ogy, and the nature of the mutant
allele (Woolf, 2003). A follow-up study
demonstrated that the penetrance
of the nogo-aEIII/EIII phenotype for
CST axonal regeneration depends on
strain background (Dimou et al.,
2006). Regenerative axon growth is
quite prominent on the Sv129 strain
background, as compared to a mixed
or C57BL/6 background (Dimou
et al., 2006).
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